Workflow
灵康药业(603669) - 2024 Q3 - 季度财报(补充)
LioncoLionco(SH:603669)2024-11-29 09:26

Financial Performance - In the first three quarters of 2024, the cash received from sales of goods and services was ¥238,867,039.41, an increase of 6.3% compared to ¥224,142,447.05 in the same period of 2023[6]. - The total cash inflow from operating activities for the first three quarters of 2024 was ¥273,547,756.34, up from ¥260,896,973.39 in 2023, reflecting a growth of 4.9%[6]. - The net cash flow from operating activities for the first three quarters of 2024 was -¥64,056,674.63, worsening from -¥21,150,724.69 in the same period of 2023[4]. Cash Flow Analysis - The cash outflow for purchasing goods and services increased significantly to ¥206,756,300.58 in 2024 from ¥107,302,510.84 in 2023, marking an increase of 92.7%[6]. - The total cash outflow from operating activities reached ¥337,604,430.97 in 2024, compared to ¥282,047,698.08 in 2023, indicating an increase of 19.7%[6]. - The company received other cash related to operating activities amounting to ¥34,680,716.93 in 2024, slightly down from ¥36,754,526.34 in 2023[6]. Reporting and Disclosure - The company expressed its commitment to improving the quality of information disclosure and enhancing the review process for periodic reports[7]. - The adjustments made to the cash flow statement do not affect the overall financial condition or operating results of the company[6]. - The company apologized for any inconvenience caused to investors due to the corrections made in the report[7]. - The revised report is available on the Shanghai Stock Exchange website for further details[6].